The Janssen EMEA team was extremely excited to present first reported primary treatment outcome data from The Prostate Cancer Registry, Europe’s first and largest prospective study of men with metastatic castration-resistant prostate cancer (mCRPC), at the European Society for Medical Oncology (ESMO) 2016 Congress over the weekend.

Jane Griffiths, Company Group Chairman, Janssen EMEA said: “Janssen is proud to support The Prostate Cancer Registry and be part of this huge endeavour which has never been attempted before. Our aim is to help provide the very best treatments for patients and improve their outcomes. It is great to see preliminary data results of treatment outcomes in mCRPC being presented at ESMO 2016. This is just the beginning and we are excited to see even further data from the Registry emerging over the coming years.”

The preliminary data suggest that chemotherapy-naïve patients benefit more from treatment than post-chemotherapy patients, and that after first line docetaxel treatment, patients have a higher prostate-specific antigen (PSA) response when treated with androgen receptor-targeted agents than with taxanes¹.

Further information around this landmark study can be found by watching our animation here.

We would like to thank everyone involved within the study for their efforts so far and are very much look forward to seeing more results over the next few years!

Key facts on mCRPC:

• mCRPC occurs when cancer has spread beyond the prostate to other parts of the body and the disease progresses despite serum testosterone below castrate levels.²
• In 2012, over 400,000 new cases of prostate cancer were diagnosed in Europe, and nearly 92,000 men died from the disease.³

back to Janssen EMEA stories